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Clinical and serologic evidence indicate that 2 American scientists contracted Zika virus infections while 
working in Senegal in 2008. One of the scientists transmitted this arbovirus to his wife after his return 
home. Direct contact is implicated as the transmission route, most likely as a sexually transmitted 
infection. 
Zika virus (ZIKV), a mosquito-transmitted flavivirus, has been isolated from sentinel 
monkeys, mosquitoes, and sick persons in Africa and Southeast Asia (1,2). Serologic surveys 
indicate that ZIKV infections can be relatively common among persons in southeastern Senegal 
and other areas of Africa, but that ZIKV-associated disease may be underreported or 
misdiagnosed. In 2007, a large outbreak of ZIKV infection occurred on Yap Island in the 
southwestern Pacific that infected ≈70% of the island’s inhabitants (3), which highlighted this 
virus as an emerging pathogen. The purpose of this study was to investigate and report 3 unusual 
cases of arboviral disease that occurred in Colorado in 2008. 
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The Study 
Two American scientists (patients 1 and 2) lived and worked in the village of Bandafassi 
in southeastern Senegal in August 2008, while performing a mosquito-sampling project in 
surrounding villages. Patients 1 and 2 were men (36 and 27 years of age, respectively), and both 
had received the yellow fever 17D vaccine before their travel to Senegal. During their project, 
both patients reported being bitten often by wild Aedes spp. mosquitoes in the evenings while 
they worked. Patients 1 and 2 left Bandafassi on August 21, stayed in Dakar for 2 days, and then 
returned to their homes in northern Colorado on August 24. Both patients became ill 6–9 days 
after their return. 
Symptoms in patient 1 began on August 30 and consisted of swollen ankles, a 
maculopapular rash on his torso, and extreme fatigue and headache, but no fever was recorded. 
On August 31, he experienced the same symptoms and light-headedness and chills, wrist and 
ankle arthalgia, and symptoms of prostatitis (perineal pain and mild dysuria). However, he 
remained afebrile. Fatigue and rash decreased on September 1; only residual wrist arthralgia, 
headache, and prostatic symptoms persisted. On September 2, two aphthous ulcers appeared on 
his lip. On September 3, he and his wife observed signs of hematospermia (red–brown fluid in 
his ejaculate) that lasted until September 7. Patient 2 experienced his symptoms during August 
29–September 1, which included a maculopapular rash on his torso, extreme fatigue, headache, 
and swelling and arthralgia in his wrists, knees, and ankles. However, symptoms of prostatitis or 
hematospermia did not devlop. Acute-phase blood samples were obtained from both patients on 
September 2. 
In patient 3 (a nurse and the wife of patient 1) similar clinical symptoms developed on 
September 3, including malaise, chills, extreme headache, photophobia, and muscle pain that 
continued through September 6. She did not have detectable fever. On September 7, a 
maculopapular rash developed on her torso (Figure) that expanded to her neck and thighs on the 
following day, and an aphthous ulcer developed on her inside lip. On September 8, arthralgia in 
her wrists and thumbs and conjunctivitis developed. Her acute symptoms waned over the next 
several days. Patient 3 had an acute-phase blood sample drawn on September 8. On September 
11, she visited her primary care physician, who performed a complete blood count test and 
studies of hepatic function; all results were within reference ranges. Patient 2 reported wrist 
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arthralgia for 1 month after his acute illness, and patients 1 and 3 have had recurring wrist or 
thumb joint arthralgia since their acute illness. Convalescent-phase blood samples were drawn on 
September 22 from patients 1 and 2 and on September 26 from patient 3. 
Acute-phase and convalescent-phase paired serum specimens from the 3 patients were 
tested independently by several different laboratories. Results of virus isolation were negative for 
all samples when tested in Vero and Aedes albopictus mosquito (C6/36) cell cultures and by 
intracerebral inoculation of acute-phase serum of patient 3 into suckling mice. Likewise, reverse 
transcriptase–PCRs with 16 different sets of arbovirus-specific primers did not detect arboviral 
RNA in any of the samples. Serologic analyses (Appendix Table) of samples from patients 1 and 
2 showed matching results. Hemagglutination inhibition antibody titers and virus neutralizing 
titers were highly elevated above background levels for ZIKV and yellow fever virus (YFV) 
compared with other viruses tested. These titers most often increased in the time between 
obtaining acute-phase and convalescent-phase serum samples. Complement fixation tests against 
ZIKV and YFV antigens confirmed these interpretations. Hemagglutination inhibition, 
complement fixation, and virus neutralizing titers against ZIKV alone developed only in the 
convalescent-phase sample of patient 3. 
Conclusions 
Evidence suggests that patients 1 and 2 were infected with ZIKV, probably in 
southeastern Senegal, by bites from infected mosquitoes. The village of Bandafassi is located in 
a disease-endemic area where ZIKV has been isolated from humans, nonhuman primates, and 
mosquitoes (4,5). Serologic results suggest an anamnestic response to ZIKV infection, likely 
stemming from their vaccination with YFV. The time between infection and the onset of clinical 
manifestations can be inferred to be >9 days, given the patients’ travel history. Their clinical 
symptoms are consistent with reported symptoms of ZIKV-associated disease (3,6–9). 
Exceptions are aphthous ulcers in patient 1 (also reported by patient 3), prostatitis, and 
hematospermia. Whether these exceptions are typical but unreported symptoms or clinical 
anomalies is not clear. 
Results also support ZIKV transmission from patient 1 to patient 3. Patient 3 had never 
traveled to Africa or Asia and had not left the United States since 2007. ZIKV has never been 
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reported in the Western Hemisphere. Circumstantial evidence suggests direct person-to-person, 
possibly sexual, transmission of the virus. Temperatures and mosquito fauna on the northern 
Front Range in Colorado when transmission occurred do not match known mosquito 
transmission dynamics of ZIKV by tropical Aedes species. Patient 3 had ZIKV disease 9 days 
after the return of her husband from Senegal. However, the extrinsic incubation period of ZIKV 
in Ae. aegypti mosquitoes was >15 days at 22°C–26°C (10). Area temperatures during the week 
of return of patient 1 fluctuated between 10°C and 31°C, only Ae. vexans mosquitoes of the 
subgenus Aedimorphus are commonly captured on the northern Colorado Front Range, and 
known tropical ZIKV vectors are mostly from the subgenus Stegomyia (4). Mosquito sampling 
around the home of patients 1 and 3 at the time yielded only 7 Ae. vexans mosquitoes and 11 
other mosquitoes of the Culex and Culiseta genera. 
Furthermore, patients 1 and 3 reported having vaginal sexual intercourse in the days after 
patient 1 returned home but before the onset of his clinical illness. It is reasonable to suspect that 
infected semen may have passed from patient 1 to patient 3 during coitus. Another possibility is 
that direct contact and exchange of other bodily fluids, such as saliva, could have resulted in 
ZIKV transmission, but illness did not develop in the 4 children of patients 1 and 3 during this 
time. 
To the best of our knowledge, human sexual transmission of an arbovirus has not been 
documented. However, Japanese encephalitis virus was discharged into the semen of 
experimentally infected boars and could infect female pigs by artificial insemination (11). 
Furthermore, West Nile virus RNA and St. Louis encephalitis virus antigen have been detected 
in urine of humans (12,13), and viruria has occurred in hamsters infected with West Nile virus 
(14) and Modoc virus (15). If sexual transmission could be verified in subsequent studies, this 
would have major implications toward the epidemiology of ZIKV and possibly other arthropod-
borne flaviviruses. 
This study was supported by grant AI079528 and contract N01-AI-25489 from the US National Institutes 
of Allergy and Infectious Diseases. 
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Figure. Maculopapular rash on patient 3 infected with Zika virus, Colorado, USA.  
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Appendix Table. Serologic results for 3 patients in whom symptoms of arboviral illness developed, northern Colorado, USA, 2008* 
Serum 
sample 
Viruses/viral antigens tested 
GETV CHIKV SINV ZIKV DENV1 DENV2 DENV3 DENV4 YFV WNV UGSV SLEV TAHV JCV LACV 
Hemagglutination inhibition test 
Pt1a 0 0 NT 5,120 2,560 640 2,560 2,560 5,120 2,560 1,280 NT 0 NT NT 
Pt1c 0 0 NT 5,120 1,280 320 1,280 1,280 2,560 1,280 1,280 NT 0 NT NT 
Pt2a 0 0 NT 1,280 160 80 320 320 1,280 160 160 NT 0 NT NT 
Pt2c 0 0 NT 2,560 160 80 320 320 1,280 160 160 NT 0 NT NT 
Pt3a 0 0 NT 0 0 0 0 0 0 0 0 NT 0 NT NT 
Pt3c 0 0 NT 320 0 0 0 0 0 0 0 NT 0 NT NT 
Plaque-reduction neutralization test 
Pt1a NT <10 <10 10,240 80 1,280 320 160 >20,480 <10 NT 80 <10 NT NT 
Pt1c NT NT NT >40,960 160 230 320 320 >40,960 160 NT NT NT NT NT 
Pt2a NT NT NT 10,240 <20 80 80 40 5,120 NT NT NT NT NT NT 
Pt2c NT NT NT 40,960 80 160 160 160 20,480 80 NT NT NT NT NT 
Pt3a NT NT NT 10 <10 <10 <10 <10 <10 <10 NT <10 NT <10 <10 
Pt3c NT NT NT 1,280 <10 <10 <10 <10 <10 <10 NT NT NT NT NT 
Complement fixation test 
Pt1a NT NT NT 64/8 NT NT NT NT 64/8 NT NT NT NT NT NT 
Pt1c NT NT NT 128/32 NT NT NT NT 64/8 NT NT NT NT NT NT 
Pt2a NT NT NT 16/8 NT NT NT NT 16/8 NT NT NT NT NT NT 
Pt2c NT NT NT 32/32 NT NT NT NT 16/8 NT NT NT NT NT NT 
Pt3a NT NT NT 0 NT NT NT NT 0 NT NT NT NT NT NT 
Pt3c NT NT NT 16/8 NT NT NT NT 0 NT NT NT NT NT NT 
*Alphaviridae: GETV, Getah virus; CHIKV, chikungunya virus; SINV, Sindbis virus; Flaviviridae: ZIK, Zika virus; DENV,  dengue virus; YFV, yellow fever virus; WNV, West 
Nile virus; UGSV, Uganda S virus; SLEV, St. Louis encephalitis virus; Bunyaviridae: TAHV, Tahyna virus; JCV, Jamestown Canyon virus; LAC, La Crosse virus; pt1, 2, and 
3, patients 1, 2, and 3, respectively; a and c, acute-phase and convalescent-phase serum samples, respectively; NT, not tested. Hemagglutination test, numbers are 
reciprocal of serum dilution inhibiting 4 units of antigen; 0 = negative reaction at a 1:20 dilution. Plaque-reduction neutralization test, numbers refer to neutralizing antibody 
titers with a 90% cutoff value: titers > positive control serum samples are indicated in boldface. Complement fixation tests, numbers refer to reciprocal of serum 
titer/repicocal of the antigen titer; 0, negative reaction at <8/<8. 
 
